Benzinga · Aug 19, 2026
Merck, Moderna Cancer Vaccine Breakthrough Could Be Catalyst the mRNA ETF Trade Has Been Waiting For
MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.
AR
BATS · ARKG
ARK Genomic Revolution ETF
Financial Services · Asset Management
$51.64
Up+$0.05 (+0.10%)
Updated Sep 20, 2026, 2:56 AM
SID Score
5.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.21B
- P/E ratio
- —
- Dividend yield
- 0.00%
- 52-week range
- $24.60 – $52.09
- Volume
- 6.73M
- Avg. volume
- 2.78M
Price performance
ARKG price history
1M range · 19 trading sessions · Daily adjusted prices
ARKG closed at $51.64 after 19 trading sessions, up 7.56% for the selected period.
- Last close
- $51.64
- Period change
- +7.56%
- Period low
- $45.38
- Period high
- $51.64
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $51.59 | $52.08 | $50.93 | $51.64 | 6.73M |
| Sep 17, 2026 | $49.05 | $52.09 | $49.05 | $51.59 | 8.58M |
| Sep 16, 2026 | $48.04 | $49.165 | $47.22 | $47.85 | 3.82M |
| Sep 15, 2026 | $46.71 | $47.835 | $46.56 | $47.71 | 3.04M |
| Sep 14, 2026 | $45.125 | $46.97 | $45.125 | $46.80 | 7.27M |
| Sep 11, 2026 | $45.76 | $46.25 | $45.29 | $45.56 | 1.76M |
| Sep 10, 2026 | $45.46 | $46.27 | $44.755 | $45.38 | 2.28M |
| Sep 9, 2026 | $46.61 | $47.21 | $46.05 | $46.31 | 2.28M |
| Sep 8, 2026 | $46.56 | $47.415 | $45.9392 | $46.85 | 2.13M |
| Sep 4, 2026 | $47.04 | $47.29 | $46.6302 | $47.14 | 1.45M |
| Sep 3, 2026 | $47.49 | $47.69 | $46.26 | $47.20 | 2.11M |
| Sep 2, 2026 | $46.95 | $48.72 | $46.08 | $47.15 | 5.45M |
| Sep 1, 2026 | $46.97 | $47.405 | $46.67 | $46.84 | 2.42M |
| Aug 31, 2026 | $47.18 | $47.425 | $46.12 | $47.23 | 3.28M |
| Aug 28, 2026 | $49.41 | $49.60 | $47.49 | $47.64 | 4.85M |
| Aug 27, 2026 | $49.37 | $50.46 | $49.16 | $49.87 | 5.3M |
| Aug 26, 2026 | $49.64 | $50.09 | $48.80 | $49.45 | 6.71M |
| Aug 25, 2026 | $48.47 | $50.535 | $48.22 | $50.06 | 5.73M |
| Aug 24, 2026 | $48.99 | $48.99 | $47.36 | $48.01 | 4.36M |
Latest ARKG news
The latest Smart Investors Daily articles mentioning ARKG.
Stock researchCompany · Overview
ARKG research
Overview
Company profile and research snapshot.
Company profile
The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
SeekingAlpha · Jul 28, 2026
ARKG: Caught In The Tech Sell-Off, But Here's Why The Dip Is Buyable
ARKG remains a Buy as its valuation improves and technical support emerges after a 15% correction from July highs. Learn more about ARKG ETF here.
Benzinga · Jun 23, 2026
Why Is Natera Stock Gaining Tuesday?
Natera (NTRA) stock rallies following a key NCCN guideline update for Signatera. Also, check out the full NTRA stock analysis.
Benzinga · Jun 18, 2026
Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF
Moderna shares have surged nearly 30% in five days, ahead of a key FDA advisory vote on its flu vaccine, lifting the leveraged MRNX ETF more than 60%.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
